| INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study (NCT04445844) | Mridula George, MD | 2020-07-13 |
| Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) (NCT04427293) | University of Illinois at Chicago | 2020-07-09 |
| Atezolizumab Plus CArboplatin Plus Nab-paclitaxel (NCT05266937) | Consorzio Oncotech | 2020-07-03 |
| Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) (NCT04434040) | Dana-Farber Cancer Institute | 2020-07-02 |
| NBE-002 in Patients With Advanced Solid Tumors (NCT04441099) | NBE-Therapeutics AG | 2020-06-19 |
| Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC (NCT04368468) | Institut Claudius Regaud | 2020-06-15 |
| NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (NCT04332653) | NeoImmuneTech | 2020-06-10 |
| Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients (NCT04418154) | Fudan University | 2020-06-09 |
| Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer (NCT05546255) | Chinese Academy of Medical Sciences | 2020-06-01 |
| Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer (NCT04142554) | UNC Lineberger Comprehensive Cancer Center | 2020-06-01 |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) (NCT04405505) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-06-01 |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer (NCT04254107) | Seagen Inc. | 2020-05-29 |
| Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer (NCT04403529) | Fudan University | 2020-05-25 |
| Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) (NCT04676997) | Shandong Cancer Hospital and Institute | 2020-05-20 |
| Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors (NCT04348916) | Oncorus, Inc. | 2020-05-20 |
| Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer (NCT04248998) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2020-05-05 |
| ImmunoBreast - A Phase Ib Study (NCT04609215) | Henrik Ditzel | 2020-04-21 |
| to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) (NCT04301739) | Shanghai Henlius Biotech | 2020-04-17 |
| Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer (NCT04134884) | Kathy Miller | 2020-04-01 |
| Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) (NCT04296175) | Fudan University | 2020-03-05 |
| Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors (NCT04142931) | Dr. Ronnie Shapira | 2020-02-24 |
| A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies (NCT04244552) | Atreca, Inc. | 2020-02-11 |
| A Multicenter Cancer Biospecimen Collection Study (NCT04510129) | Cofactor Genomics, Inc. | 2020-02-05 |
| A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment (NCT04178460) | Zai Lab (Shanghai) Co., Ltd. | 2020-02-03 |
| Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy (NCT04437160) | Chinese Academy of Medical Sciences | 2020-02-01 |
| SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer (NCT04213898) | Henan Cancer Hospital | 2020-01-01 |
| Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy (NCT04225858) | The Netherlands Cancer Institute | 2020-01-01 |
| A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer (NCT04148911) | Hoffmann-La Roche | 2019-12-10 |
| Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients (NCT04068623) | Centre Jean Perrin | 2019-12-04 |
| Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour (NCT04107142) | CytoMed Therapeutics Pte Ltd | 2019-12-01 |
| A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer (NCT04177108) | Hoffmann-La Roche | 2019-11-25 |
| fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases (NCT06328465) | European Institute of Oncology | 2019-11-22 |
| Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer (NCT04159142) | Hebei Medical University Fourth Hospital | 2019-11-20 |
| Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer (NCT04138719) | Hebei Medical University Fourth Hospital | 2019-11-20 |
| Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression (NCT04180371) | BicycleTx Limited | 2019-11-07 |
| A Study of LY3435151 in Participants With Solid Tumors (NCT04099277) | Eli Lilly and Company | 2019-10-28 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (NCT03997968) | Cyteir Therapeutics, Inc. | 2019-10-09 |
| A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS) (NCT04129996) | Fudan University | 2019-10-01 |
| LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer (NCT04032080) | Baylor Research Institute | 2019-09-05 |
| Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer (NCT04083963) | University of Illinois at Chicago | 2019-08-09 |
| Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer (NCT03981705) | Masonic Cancer Center, University of Minnesota | 2019-08-08 |
| Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer (NCT04030507) | Brigham and Women's Hospital | 2019-07-26 |
| Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (NCT03199040) | Washington University School of Medicine | 2019-07-23 |
| A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer (NCT04750382) | Taizhou Hanzhong biomedical co. LTD | 2019-07-15 |
| A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients (NCT03945721) | Massachusetts General Hospital | 2019-07-11 |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) (NCT03992131) | pharmaand GmbH | 2019-06-28 |
| A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (NCT03901469) | Zenith Epigenetics | 2019-06-26 |
| Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer (NCT03932526) | Liaoning Cancer Hospital & Institute | 2019-06-24 |
| Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (NCT03812393) | West Cancer Center | 2019-06-21 |
| Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) (NCT03674242) | ERYtech Pharma | 2019-06-13 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors (NCT04234113) | SOTIO Biotech AG | 2019-06-13 |
| A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC (NCT03945604) | Jiangsu HengRui Medicine Co., Ltd. | 2019-06-04 |
| A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer (NCT03872791) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2019-05-30 |
| A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (NCT03849469) | Xencor, Inc. | 2019-05-29 |
| PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients (NCT03251313) | Fudan University | 2019-05-15 |
| Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC (NCT04067102) | Hebei Medical University Fourth Hospital | 2019-05-10 |
| Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (NCT03620643) | Royal Marsden NHS Foundation Trust | 2019-05-09 |
| Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (NCT03891953) | Novartis Pharmaceuticals | 2019-05-07 |
| Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NCT04024800) | NuGenerex Immuno-Oncology | 2019-05-03 |
| Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients (NCT04145947) | Peking Union Medical College Hospital | 2019-04-25 |
| Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer (NCT03907800) | Ruijin Hospital | 2019-04-01 |
| Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer (NCT03644589) | University of Washington | 2019-04-01 |
| Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) (NCT03752723) | Genexine, Inc. | 2019-03-27 |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (NCT03829436) | Tempest Therapeutics | 2019-03-20 |
| Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer (NCT04362462) | Texas Tech University Health Sciences Center, El Paso | 2019-03-05 |
| The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency (NCT03876886) | Chinese Academy of Medical Sciences | 2019-02-22 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) (NCT03797326) | Merck Sharp & Dohme LLC | 2019-02-12 |
| A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies (NCT03829501) | Kymab Limited | 2019-01-28 |
| Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease (NCT03808337) | Memorial Sloan Kettering Cancer Center | 2019-01-16 |
| Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung (NCT03808662) | Memorial Sloan Kettering Cancer Center | 2019-01-16 |
| Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer (NCT03756298) | National Cancer Center, Korea | 2019-01-15 |
| Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer (NCT03599453) | Roswell Park Cancer Institute | 2019-01-09 |
| Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer (NCT03654547) | TransThera Sciences (Nanjing), Inc. | 2019-01-08 |
| TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer (NCT03720431) | PharmAbcine | 2019-01-03 |
| Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC (NCT06700382) | Shu Wang | 2019-01-01 |
| De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC (NCT06692725) | Peking University People's Hospital | 2019-01-01 |
| Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC (NCT03616886) | Jules Bordet Institute | 2018-12-28 |
| A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC (NCT03777579) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2018-12-21 |
| Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment (NCT04085276) | Shanghai Junshi Bioscience Co., Ltd. | 2018-12-21 |
| Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC (NCT05498896) | Queen Mary University of London | 2018-12-19 |
| A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors (NCT03775850) | Evelo Biosciences, Inc. | 2018-12-19 |
| Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer (NCT03775928) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2018-12-18 |
| Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC (NCT03562637) | OBI Pharma, Inc | 2018-12-05 |
| Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC (NCT03674827) | Pfizer | 2018-11-27 |
| Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer (NCT03799679) | Fudan University | 2018-11-26 |
| Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC (NCT04664972) | Henan Cancer Hospital | 2018-11-23 |
| MGC018 With or Without MGA012 in Advanced Solid Tumors (NCT03729596) | MacroGenics | 2018-11-21 |
| ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer (NCT03733119) | University of Wisconsin, Madison | 2018-11-13 |
| Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (NCT03621982) | ADC Therapeutics S.A. | 2018-11-09 |
| MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC (NCT03881605) | Sunnybrook Health Sciences Centre | 2018-11-08 |
| FUSCC Refractory TNBC Umbrella (FUTURE) (NCT03805399) | Fudan University | 2018-10-18 |
| Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC (NCT03567720) | OncoSec Medical Incorporated | 2018-10-11 |
| Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (NCT03167619) | Duke University | 2018-10-04 |
| Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer (NCT03617341) | Yonsei University | 2018-10-02 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer (NCT03634150) | Immune System Key Ltd | 2018-09-06 |
| COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (NCT03667716) | Compugen Ltd | 2018-09-06 |
| Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer (NCT03639948) | University of Kansas Medical Center | 2018-09-04 |
| A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (NCT03498716) | Hoffmann-La Roche | 2018-08-02 |